The status of cannabis legalisation in the UK and the EU has evolved, with some countries and regions taking steps towards legalisation or decriminalising cannabis for both medical and recreational use.
In this article, I will be providing an overview of the growth of legalising cannabis in the UK and EU and how it relates to the therapeutic applications of cannabis.
Medical Cannabis in the UK
The growth of medical cannabis in the United Kingdom has been a complex and gradual process, marked by changes in legislation, shifting public perception, and the recognition of the potential therapeutic benefits of cannabis-based products. In November 2018, the UK legalised the use of cannabis-based products for medicinal use. However, this was limited to a very small number of specific conditions, and access remained restricted. Licensed healthcare professionals were allowed to prescribe cannabis-based products, but this was done on a case-by-case basis.
The actual availability of medical cannabis products remained limited due to various factors, including the reluctance of some doctors to prescribe them, issues with importation, and the high cost of some products. Research into the medical applications of cannabis and cannabinoids continued to grow, with more clinical trials and studies conducted to assess their effectiveness in treating various conditions.
Medical Cannabis in the EU
The status of medical cannabis varied across European countries. Some countries in the EU had established medical cannabis programs, while others were still in the process of developing regulations. For example, Germany had a well-established medical cannabis program, and countries like the Netherlands had long-standing policies allowing the sale of cannabis in designated "coffee shops" for recreational use.
Medical cannabis research was ongoing in several EU countries, with a focus on assessing its effectiveness and safety for various medical conditions. Clinical trials were being conducted to gather more data on its potential therapeutic benefits. The EU was considering harmonising regulations related to medical cannabis to ensure consistency and quality standards across member states. However, this process was still in the early stages in 2021.
Public attitudes towards medical cannabis were evolving, with increased awareness of its potential medical benefits and with this remained some stigma and misconceptions around the use of cannabis for medical purposes. Furthermore, as information becomes available about the potential therapeutic benefits of medical cannabis the stigma has reduced. Many people now view medical cannabis as a legitimate form of treatment for certain medical conditions rather than simply as a recreational drug.
The Relationship to Therapeutic Applications:
Research and Development: The legalisation of medical cannabis in the UK and EU provided opportunities for research and development of cannabis-based medicines. Companies and researchers were exploring the therapeutic potential of cannabinoids like CBD (cannabidiol) and THC (tetrahydrocannabinol) for various medical conditions, including chronic pain, epilepsy, multiple sclerosis, and more
Patient Access: Legalisation allowed patients suffering from specific medical conditions to access cannabis-based medicines under the supervision of healthcare professionals. This was particularly important for patients who had not responded well to traditional treatments
Regulation and Quality Control: Legalisation brought about regulations to ensure the safety and quality of medical cannabis products. These regulations included standards for cultivation, processing, and distribution to ensure that patients received reliable and standardised products
Economic Opportunities: The rise of licensed cannabis businesses in the UK and EU created economic opportunities. This included the cultivation, processing, and distribution of medical cannabis products, as well as the development of a skilled workforce in the cannabis industry
Public Perception: As medical cannabis became more accepted and accessible, it helped change public perceptions of cannabis from a recreational drug to a potential therapeutic option
In conclusion, medical cannabis in the UK and the EU offers several potential benefits, particularly in managing pain and certain medical conditions. However, it also comes with significant challenges related to regulation, research, and public perception. Striking a balance between providing access to those who can benefit from it and mitigating potential risks will continue to be a complex issue for policymakers and healthcare professionals in these regions.
The relationship between therapeutic applications and cannabis in the UK and EU is marked by a delicate balance between potential benefits and regulatory challenges. As the scientific understanding of cannabis continues to grow, it is essential to maintain a cautious and informed approach to ensure that patients receive safe and effective treatments while mitigating potential risks and challenges associated with cannabis-based therapies.
Mantell Associates is a specialist Pharmaceutical and Life Sciences headhunting firm. To find out how we can assist with your business requirements, get in touch with Tom Bryan at +44 2038 547700 or email@example.com.
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA -https://www.emcdda.europa.eu/
PubMed - https://pubmed.ncbi.nlm.nih.gov/
Cannabis Business Times - https://www.cannabisbusinesstimes.com/
Brookings Institution https://www.brookings.edu/